Lucknow Hospital's New Rule: Imported Implants Face Strict Approval for Poor Patients

Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
King George's Medical University (KGMU) in Lucknow has recently implemented a new policy, effective September 10, 2026, mandating prior written approval for doctors to use expensive imported medical implants for poor patients, including those covered under the national Ayushman Bharat Yojana. This directive, issued by the chief medical superintendent, aims to prioritize high-quality and affordable Indian-made implants when suitable alternatives are available, marking a significant shift in publicly funded healthcare procurement. The move underscores a growing national emphasis on cost-effectiveness and supporting local manufacturing, while sparking a critical debate on patient choice and access to advanced medical technology. The policy comes amidst India's broader push for self-reliance under the 'Make in India' initiative, with the country still importing nearly 70% of its medical devices despite rapid domestic sector growth. While Ayushman Bharat offers up to ₹5 lakhs in annual health coverage, including implants, the KGMU decision raises the fundamental question of whether government funding should dictate the range of clinically appropriate options for patients, especially when domestic alternatives are deemed comparable. This aligns with ongoing discussions, like those by the Maharashtra FDA, concerning massive markups between procurement prices and the Maximum Retail Price of medical devices, adding pressure on hospitals to manage costs. Looking ahead, this localized policy change at KGMU could set a precedent for other public healthcare institutions in India, potentially reshaping procurement practices across the country. Healthcare professionals and policymakers will closely watch its impact on patient outcomes, cost efficiencies, and the growth of India's indigenous medical device industry. The ethical considerations around patient choice and the balance between affordability and access to global medical advancements will likely fuel further debate as the policy takes root.